|
| Status |
Public on Jan 31, 2008 |
| Title |
Phase II exploratory pharmacogenomics study of cetuximab monotherapy in patients with advanced metastatic CRC |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Patients with metastatic colorectal cancer were enrolled for treatment with cetuximab monotherapy. Transcriptional profiling was conducted on RNA from pre-treatment metastatic site biopsies to identify genes whose expression correlates with best clinical responses.
Keywords: comparison of disease control group versus non-responder group of patients
|
| |
|
| Overall design |
single pre-treatment metastatic biopsy from each patient analyzed
|
| |
|
| Contributor(s) |
Khambata-Ford S, Garrett CR, Huang X, Mauro DJ |
| Citation(s) |
17664471 |
| Submission date |
Sep 15, 2006 |
| Last update date |
Dec 06, 2018 |
| Contact name |
Shirin Khambata Ford |
| E-mail(s) |
shirin.ford@bms.com
|
| Organization name |
Bristol-Myers Squibb Pharmaceutical Research Institute
|
| Street address |
311 Pennington-Rocky Hill Road, 3B-2.06
|
| City |
Pennington |
| State/province |
NJ |
| ZIP/Postal code |
08534 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL571 |
[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array |
|
| Samples (80)
|
|
| Relations |
| BioProject |
PRJNA97257 |
Less...
More...